Lv1
78 积分 2022-10-17 加入
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
1个月前
已完结
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
1个月前
已完结
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study
1年前
已关闭
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma A Phase 2 Nonrandomized Clinical Trial
1年前
已完结
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
1年前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1年前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
1年前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
1年前
已完结
Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma A Randomized Clinical Trial
1年前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
1年前
已完结
皖公网安备34019202002308
